Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New brain scanner could sharpen epilepsy surgery targeting

NCT ID NCT07281222

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new, more comfortable brain scanner (OPM MEG) that fits directly on the head to locate where seizures start in people with epilepsy. Researchers will compare its accuracy to standard methods in 70 patients aged 6 to 65 who are already scheduled for epilepsy surgery. If the device proves reliable, it could help surgeons remove the right brain area and improve seizure control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OPM MEG device (FYNA Research)
What this could lead to
If successful, this could provide a more accurate, comfortable, and accessible way to pinpoint seizure origins, potentially improving surgical outcomes for epilepsy patients.
What could go wrong
This is an early-stage diagnostic study with only 70 participants. The device may not prove more accurate than existing methods, and results may not generalize to all epilepsy types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 6 to 65 2. Patients suffering from partial epilepsy that has been developing for at least 2 years, drug-resistant, regardless of the presumed topographical origin or suggested cause (lesional with or without MRI abnormality) and for whom the following have been decided and planned: either i) a surgical procedure to resect the epileptogenic zone without prior intracranial EEG recording or ii) intracranial EEG recording necessary before a possible cortical resection procedure 3. Patients who have undergone routine prolonged scalp video EEG recording showing interictal paroxysmal abnormalities 4. Patients motivated to participate effectively in the project 5. Patients who have signed an informed consent form to participate in the study Exclusion Criteria: 1. Patients with neurological or psychiatric disorders or a history of neurological or psychiatric disorders, sleep disorders other than epilepsy that may impact the variability or quality of the data or the cooperation and retention of the participant, which will be assessed by the principal investigator or co-investigator during the inclusion interview. 2. Patients with contraindications common to MEG and MRI examinations: * Metal in the body that is incompatible with the examination (pacemaker, implanted pump including insulin pump, neurostimulator, cochlear implants or other hearing devices, metal prosthesis, intracerebral/surgical clips for aneurysms, implantable defibrillators, ferromagnetic foreign bodies in the eyes or brain in the upper body, ventriculoperitoneal neurosurgical shunt valves, dental braces or steel pivots for dental root canals, ferromagnetic foreign bodies in the upper body) * Claustrophobia 3. Pregnant women, breastfeeding women, or women who have given birth within the last 6 months. 4. Patients under guardianship, curatorship, or judicial protection 5. Patients deprived of their liberty 6. Patients not affiliated with a social security system or beneficiaries of such a system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug-resistant partial epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Service Explorations Fonctionnelles Pédiatriques

    Bron, 69500, France

  • Hôpital Neurologique, Hospices Civils de Lyon, Service Explorations Fonctionnelles Neurologiques et Epileptologie

    Bron, 69500, France

  • Hôpital de la Timone, AP-HM Service d'Epileptologie et Rythmologie Cérébrale

    Marseille, 13005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.